Previous 10 | Next 10 |
Can-Fite Biopharma press release ( NYSE: CANF ): 1H GAAP EPS of $0.00 beats by $0.09 . Revenue of $0.4M (+2.6% Y/Y) beats by $0.15M . On June 30, 2022, the company had approximately $12.72 million in cash, cash equivalents, and short-term deposits. For fu...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2022. Corporate ...
The shares of Israeli biotech Can-Fite BioPharma ( NYSE: CANF ) climbed ~18% in pre-market trading Monday after the company announced that Romania approved its liver disease candidate Namodenoson for compassionate use in advanced liver cancer. Previously Israel also ap...
Namodenoson induced a complete response with disappearance of all metastases in a patient who will now continue the treatment under a compassionate use program in Romania Can Fite’s Phase III pivotal study is open for patient enrolment Can-Fite B...
Presentation by study’s co-author Dr. Kim Papp, a Key Opinion Leader who has completed over 150 studies and worked on numerous drugs now on the market Dr. Papp is designing Can-Fite’s pivotal Phase III psoriasis registration trial Can-Fite...
Safety study successfully completed; efficacy trial to commence and financially covered by Vetbiolix Canine osteoarthritis market is projected to reach $3 billion by 2028 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology comp...
Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...
Further analysis of Phase III COMFORT ™ data show Piclidenoson’s superior safety profile and higher patient compliance compared to Otezla ® Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company ...
Renalytix ( RNLX ) -28% on Q3 earnings release . Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease . Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq com...
Can-Fite BioPharma's ( NYSE: CANF ) oral drug piclidenoson helped reduce severity of symptoms compared to placebo, but failed to beat Amgen's ( AMGN ) Otezla in adult patients with moderate to severe plaque psoriasis in a phase 3 trial. Plaque psoriasis cau...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...